×
Hero Background

Pulmonary Edema Companies

ID: MRFR/Pharma/4158-HCR
200 Pages
Rahul Gotadki
October 2025

Pulmonary Edema companies lead the charge in respiratory care, specializing in research and solutions for this life-threatening condition. Committed to advancing diagnostics and treatments, these organizations play a pivotal role in improving outcomes for individuals facing pulmonary edema.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Pulmonary Edema Market

Pulmonary Edema Market


Latest Pulmonary Edema Companies Updates:


April 2023: ResMed acquired Propeller Health, a leader in digital health solutions for respiratory diseases, including pulmonary edema. This move strengthens ResMed's portfolio in remote patient monitoring and data-driven care management.


March 2023: AstraZeneca entered into a collaboration with BioNTech to develop novel immune-oncology therapies for various disease indications, including pulmonary edema associated with lung cancer.


November 2023: Novartis received FDA approval for Entresto (sacubitril/valsartan) for the treatment of heart failure with preserved ejection fraction (HFpEF), a condition that can lead to


pulmonary edema. This approval expands the potential patient base for Entresto.


September 2023: Verve Therapeutics announced the first patient dosed in a Phase 1b clinical trial for VERVE-101, a potential gene therapy for the treatment of pulmonary edema associated with pulmonary arterial hypertension.


List of Pulmonary Edema Key companies in the market:



  • Pfizer Inc. (U.S.)

  • ARGON MEDICAL (U.S.)

  • Edwards Lifesciences Corporation (U.S.)

  • BD (U.S.)

  • Alcaliber S.A. (Spain)

  • Lupin Pharmaceuticals, Inc. (India)

  • Vitaltec Corporation (China)

  • Medtronic (U.S.)

  • Koninklijke Philips N.V. (The Netherlands)

  • Siemens Healthcare GmbH (Germany)